Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote

Dow Jones

06/17

By Grace Yoon

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February.

Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said.

"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease," Chief Executive Eric Dube said.

Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said.

Write to Grace Yoon at grace.yoon@wsj.com.

- -

(END) Dow Jones Newswires

June 16, 2026 17:13 ET (21:13 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2644798730"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2644798730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2644798730?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644798730","market":"sh","top_or_hot":-1,"title":"Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Grace Yoon \n</p>\n<p>\n  Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Chief Research Officer William Rote plans to retire from the company in February. \n</p>\n<p>\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n</p>\n<p>\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n</p>\n<p>\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n</p>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-17 05:13</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Grace Yoon \n</p>\n<p>\n  Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said Chief Research Officer William Rote plans to retire from the company in February. \n</p>\n<p>\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n</p>\n<p>\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n</p>\n<p>\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n</p>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2026 17:13 ET (21:13 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644798730","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644798730","pubTimestamp":1781644380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February.Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said.\"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said.Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","TVTX":"Travere Therapeutics, Inc.","BK4007":"制药","BK4539":"次新股","BK4139":"生物科技","FFTY":"Innovator IBD 50 ETF"},"translate_title":"Travere Therapeutics任命Inrig为新任研究主管，接替Rote","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9,"FFTY":1.5,"LENZ":1.5},"content_text":"By Grace Yoon \n\n\n  Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. \n\n\n  Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's research organization and be named executive vice president, head of research and development and along with her medical chief role, Travere said. \n\n\n  \"Since joining Travere in 2017, Bill has played a pivotal role in transforming our company into a recognized leader in rare disease,\" Chief Executive Eric Dube said. \n\n\n  Inrig joined the biopharmaceutical company in 2022 as CMO, overseeing clinical development and operations. She previously served as the global head of the Renal Center of Excellence at Iqvia, leading the design of programs that supported regulatory approvals in kidney disease, the company said. \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com. \n\n\n- - \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 17:13 ET (21:13 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}